S-2529-119
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sponsored by Jon Husted (R-OH)
What it does
This bill would amend the Federal Food, Drug, and Cosmetic Act to make the FDA's process for approving prescription drugs as over-the-counter (OTC) products clearer and more predictable. It would require the FDA to issue guidance within 18 months on evidentiary standards for these applications, establish formal pre-application meetings between drug sponsors and the FDA, and publish a stakeholder engagement plan within one year. It would also direct the Government Accountability Office (GAO) to report on the current state of the Rx-to-OTC switch process, including approval timelines, barriers, and opportunities for collaboration between FDA and CMS.
Who benefits
Pharmaceutical companies seeking to switch their prescription drugs to OTC status, who would gain clearer guidance and a more predictable approval pathway. Consumers who could gain access to medications currently requiring a doctor's visit, potentially at lower cost and with greater convenience. Patients in underserved or rural areas with limited access to physicians. Retail pharmacies and OTC drug retailers who would gain new products. Health insurers and employers, if OTC access reduces costly physician visits. Generic drug manufacturers who could more easily enter the OTC market once a switch pathway is clarified.
Who is hurt
Physicians and other prescribers who may see reduced patient visits if more drugs become available OTC. Pharmacy benefit managers and insurers whose formulary leverage may shift if drugs move off prescription status. Patients who rely on physician oversight to manage complex conditions and who could be harmed by unsupervised use of switched drugs. Consumer safety advocates concerned that clearer pathways could accelerate switches before sufficient real-world safety data exists. Specialty pharmacies that depend on prescription-only drug volume.
Supporters argue
Supporters argue that the current Rx-to-OTC switch process is opaque and unpredictable, discouraging manufacturers from pursuing switches even for drugs with well-established safety profiles. They contend that expanding OTC access reduces barriers to care — particularly for the roughly 25% of Americans who lack a regular primary care provider — and that countries like the UK and Canada have already made OTC many drugs still prescription-only in the U.S. They argue the bill does not lower safety standards but simply clarifies what evidence the FDA already requires, reducing costly uncertainty for applicants.
Opponents argue
Opponents argue that streamlining the switch process risks prioritizing speed and commercial interest over patient safety, particularly for drugs with narrow therapeutic windows or misuse potential. They contend that the bill's requirement for FDA guidance within 18 months may pressure the agency to issue standards before adequate evidence is gathered, and that the GAO report's focus on CMS claims data raises privacy and scope concerns. They further argue that without physician oversight, patients may self-diagnose incorrectly, use drugs inappropriately, or delay seeking care for serious underlying conditions.
Constitutional context
Congress has broad authority to regulate drug approval processes under the Commerce Clause (Art. I, §8, cl. 3) and the Necessary and Proper Clause (Art. I, §8, cl. 18). This bill directs FDA rulemaking and guidance, which post-Loper Bright (2024) means any resulting agency guidance will be subject to independent judicial review rather than automatic deference, potentially increasing legal vulnerability of the standards FDA issues under this mandate.
Checks and balances
Congress gains authority by directing FDA timelines and guidance content; the FDA retains discretion over specific approval decisions; courts may independently review any resulting agency guidance under the post-Loper Bright standard; the GAO provides independent oversight through its mandated report.
Historical precedent
The FDA Modernization Act of 1997 and subsequent guidance documents have previously attempted to clarify the Rx-to-OTC switch process, though no single statute has codified the evidentiary and procedural standards this bill would require.